Benay Taub Lung Cancer Research Act
Summary
HR6319 is an early-stage bill that establishes a Lung Cancer Task Force within NIH to study research disparities, funding levels, and screenings. It authorizes no funding and creates no direct revenue or cost impact on any publicly traded company. No market action is justified at this stage.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.Zero funding or spending authorized — no money trail for investors
- 2.Merely establishes a study task force with no binding recommendations
- 3.Early procedural stage with no committee action since Nov 2025
- 4.No identified tickers — no causal chain from bill text to any public company revenue
Market Implications
No market implications. HR6319 is a study-authorization bill with zero appropriations. It does not change the competitive dynamics, revenue outlook, or regulatory burden for any publicly traded company in lung cancer diagnostics, therapeutics, or screening. Retail investors should ignore this legislation until and unless it advances to a funding stage.
Full Analysis
- On November 28, 2025, Rep. Gottheimer (D-NJ) introduced HR6319, the Benay Taub Lung Cancer Research Act. It was immediately referred to the House Committee on Energy and Commerce and has had no further action since referral. The bill is in its earliest legislative stage with zero committee hearings, markups, or votes. 2) The bill text creates a task force within NIH to examine lung cancer research disparities relative to other diseases, federal funding levels, and screening rates. It does not authorize or appropriate any dollar amount. The task force must report findings and recommendations to Congress within 180 days of enactment. There is no procurement mandate, no grant program, no tax credit, and no regulatory requirement directed at private companies. 3) Without funding or any binding directive, there are no structural winners or losers in publicly traded equities. Companies with exposure to lung cancer diagnostics, therapeutics, or screening technology — such as $LLY (oncology pipeline), $JNJ (lung cancer drugs), $BMY (Opdivo), $MRK (Keytruda), or screening firms like $ILMN (genomic sequencing) — have zero direct revenue channel from this procedural bill. 4) The bill has only 4 cosponsors, all junior members, and sits in the Commerce Committee. No companion bill exists in the Senate. Legislative velocity is minimal. 5) Remaining steps: committee consideration, potential markup, House vote, Senate introduction/passage, presidential signature. Given the procedural nature and zero funding authorization, this bill has effectively no timeline pressure or market relevance for at least 12-18 months, if ever.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
To amend title XVIII of the Social Security Act to ensure equitable payment for, and preserve Medicare beneficiary access to, cancer treatments under the Medicare hospital outpatient prospective payment system.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Protecting Americans from Unsafe Drugs Act of 2026
American Innovation and R&D Competitiveness Act of 2025
DLA TROOP SUPPORT: $65.0M Department of Health and Human Services Contract
Most Favored Patient Act of 2026
Lowering Drug Costs for American Families Act
Skinny Labels, Big Savings Act
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Regulatory Relief for Certain Stationary Sources to Promote American Chemical Manufacturing Security
President Trump issued a proclamation exempting certain chemical manufacturing facilities from compliance with the EPA's HON Rule for two years, citing unavailability of required technology and national security concerns. The exemption delays emissions-control deadlines and maintains pre-HON Rule standards for listed stationary sources, invoking authority under Clean Air Act section 112(i)(4).
Advancing Regenerative Agriculture and Strengthening American Farm Resilience
This executive order directs the EPA, USDA, and HHS to prioritize registration of alternative pesticides, expedite cumulative exposure research, and maximize funding for a regenerative agriculture pilot program, while creating public-private partnerships to expand adoption of conservation farming practices. The order specifically instructs the EPA Administrator to speed up registration actions for substances that can replace older active ingredients, and requires HHS to issue a grand prize challenge for cumulative chemical exposure evaluation technologies.
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →